Ownership history in FEDERATED HERMES, INC. Β· 23 quarters on record
This page tracks every 13F SEC filing in which FEDERATED HERMES, INC. reported a position in ARCTURUS THERAPEUTICS HLDG I (ARCT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π FEDERATED HERMES, INC. underperformed the S&P 500 by β33.5% annually on this ARCT position. Timing score: 53% (8/15 decisions correct). Average cost basis: $37.48. Maximum drawdown during holding period: β87.2%.
β Significantly underperformed the S&P 500 by 33.5% ann.
22 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
8 of 15 add/trim decisions correct
Best entry: $14.82 (2022 Q3) Β· Worst: $47.78 (2021 Q3)
πͺ Held through 2 major drawdowns (>20%).
9 adds Β· 7 trims. Bought during 4 of 13 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.03% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size